Drug-induced QT interval shortening: Potential harbinger of proarrhythmia and regulatory perspectives

British Journal of Pharmacology

Volumn 159, Issue 1, 2010, Pages 58-69

  Shah, Rashmi R ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

Action potential; Lamotrigine; LQTS; QT interval; Rufinamide; SQTS; Torsade de pointes; Ventricular fibrillation

Indexed keywords

LEMAKALIM; MELPERONE; PINACIDIL; QUINIDINE; RUFINAMIDE; THIORIDAZINE;

CORRELATION ANALYSIS; DRUG SAFETY; ELECTROPHYSIOLOGY; GENOTYPE; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HUMAN; MUTATIONAL ANALYSIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SHORT QT SYNDROME;

ANIMALS; ANTICONVULSANTS; DRUG APPROVAL; DRUG DESIGN; HUMANS; KATP CHANNELS; LEGISLATION, DRUG; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; TRIAZOLES;

EID: 74549126556     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00191.x     Document Type: Review

References (119)

1. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME (2003). Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 78 : 1479 1487.
2. Ackerman MJ, Splawski I, Makielski JC, Tester DJ, Will ML, Timothy KW et al. (2004). Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm 1 : 600 607.
3. Aerssens J, Paulussen AD (2005). Pharmacogenomics and acquired long QT syndrome. Pharmacogenomics 6 : 259 270.
4. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J (1993). QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. Br Heart J 70 : 43 48.
5. Amin AS, Herfst LJ, Delisle BP, Klemens CA, Rook MB, Bezzina CR et al. (2008). Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome. J Clin Invest 118 : 2552 2561.
6. Anttonen O, Junttila MJ, Rissanen H, Reunanen A, Viitasalo M, Huikuri HV (2007). Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population. Circulation 116 : 714 720.
7. Anttonen O, Väänänen H, Junttila J, Huikuri HV, Viitasalo M (2008). Electrocardiographic transmural dispersion of repolarization in patients with inherited short QT syndrome. Ann Noninvasive Electrocardiol 13 : 295 300.
8. Antzelevitch C, Oliva A (2006). Amplification of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes. J Intern Med 259 : 48 58.
9. Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y et al. (2007). Loss of function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 115 : 442 449.
10. Asami T, Suzuki H, Yazaki S, Sato S, Uchiyama M (2001). Effects of thyroid hormone deficiency on electrocardiogram findings of congenitally hypothyroid neonates. Thyroid 11 : 765 768.
11. Aström-Lilja C, Odeberg JM, Ekman E, Hägg S (2008). Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 17 : 587 592.
12. Aurlien D, Leren TP, Taubøll E, Gjerstad L (2009). New SCN5A mutation in a SUDEP victim with idiopathic epilepsy. Seizure 18 : 158 160.
13. Bal JS, Thuluvath PJ (2003). Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 23 : 243 248.
14. Bellet S, Finkelstein D (1951). Significance of QT prolongation in the electrocardiogram: based on the study of 168 cases. Am J Med Sci 222 : 263 278.
15. Bellocq C, van Ginneken AC, Bezzina CR, Alders M, Escande D, Mannens MM et al. (2004). Mutation in the KCNQ1 gene leading to the short QT interval syndrome. Circulation 109 : 2394 2397.
16. Berge KE, Haugaa KH, Fruh A, Anfinsen OG, Gjesdal K, Siem G et al. (2008). Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers. Scand J Clin Lab Invest 68 : 362 368.
17. Bezzina CR, Verkerk AO, Busjahn A, Jeron A, Erdmann J, Koopmann TT et al. (2003). A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res 59 : 27 36.
18. Borggrefe M, Wolpert C, Antzelevitch C, Veltmann C, Giustetto C, Gaita F et al. (2005). Short QT syndrome. Genotype-phenotype correlations. J Electrocardiol 38 (Suppl. 4 75 80.
19. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M et al. (2004). Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109 : 30 35.
20. Buxton AE, Calkins H, Callans CJ, DiMarco JP, Fisher JP, Greene HL et al. (2006). ACC/AHA/HRS 2006 key data elements and definitions for electrophysiology studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). J Am Coll Cardiol 48 : 2360 2396. (Pubitemid 44856764)
21. Casis O, Olesen SP, Sanguinetti MC (2006). Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol Pharmacol 69 : 658 665.
22. Cerrone M, Noujaim S, Jalife J (2006). The short QT syndrome as a paradigm to understand the role of potassium channels in ventricular fibrillation. J Intern Med 259 : 24 38.
23. Chinushi M, Aizawa Y, Furushima H, Inuzuka H, Ojima K, Shibata A (1995). Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome. Jpn Heart J 36 : 477 481.
24. CPMP (1997). Committee for Proprietary Medicinal Products Points to Consider: the Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products (CPMP/986/96). EMEA : London, 17 December 1997. http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs%5Ccpmp.pdf [Accessed on 27 December 2009 L, Celano G, Dagradi F, Schwartz PJ (2008). Congenital long QT syndrome. Orphanet J Rare Dis 3 : 18 33.
25. Curione M, Letizia C, Amato S, Di Bona S, Di Fazio F, Minisola S et al. (2007). Increased risk of cardiac death in primary hyperparathyroidism: what is a role of electrical instability? Int J Cardiol 121 : 200 202.
26. Dennis A, Wang L, Wan X, Ficker E (2007). hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35 (Pt 5 1060 1063.
27. DeSilvey DL, Moss AJ (1980). Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression. Ann Intern Med 93 : 53 54.
28. Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K et al. (2008). Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 66 : 396 404.
29. Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM et al. (2004). Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation 110 : 2721 2746.
30. + channels in guinea-pig cardiac myocytes. Pflugers Arch 414 : 669 675.
31. Extramiana F, Antzelevitch C (2004). Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular wedge model of short QT syndrome. Circulation 110 : 3661 3666.
32. Extramiana F, Maury P, Maison-Blanche P, Duparc A, Delay M, Leenhardt A (2008). Electrocardiographic biomarkers of ventricular repolarisation in a single family of short QT syndrome and the role of the Bazett correction formula. Am J Cardiol 101 : 855 860.
33. Fei L, Statters DJ, Gill JS, Katritsis D, Camm AJ (1994). Alteration of the QT/RR relationship in patients with idiopathic ventricular tachycardia. Pacing Clin Electrophysiol 17 : 199 206.
34. Fichet J, Genee O, Pierre B, Babuty D (2008). Fatal QT interval. Am J Emerg Med 26 : 739.
35. FDA (2008). Label for BANZEL (rufinamide). http://www.fda.gov/cder/foi/ label/2008/021911lbl.pdf [Accessed on 4 January 2009 GR, Froggatt P, James TN (1964a). Congenital deafness associated with electrocardiographic abnormalities, fainting attacks and sudden death. A recessive syndrome. Quart J Med 33 : 361 385.
36. Fraser GR, Froggatt P, Murphy T (1964b). Genetical aspects of the cardio-auditory syndrome of Jervell and Lange-Nielsen (congenital deafness and electrocardiographic abnormalities). Ann Hum Genet 28 : 133 157.
37. Fujiki A, Sugao M, Nishida K, Sakabe M, Tsuneda T, Mizumaki K et al. (2004). Repolarization abnormality in idiopathic ventricular fibrillation: assessment using 24-hour QT-RR and QaT-RR relationships. J Cardiovasc Electrophysiol 15 : 59 63.
38. Funada A, Hayashi K, Ino H, Fujino N, Uchiyama K, Sakata K et al. (2008). Assessment of QT intervals and prevalence of short QT syndrome in Japan. Clin Cardiol 31 : 270 274.
39. Furutani M, Trudeau MC, Hagiwara N, Seki A, Gong Q, Zhou Z et al. (1999). Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation 99 : 2290 2294.
40. Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R et al. (2003). Short QT syndrome: a familial cause of sudden death. Circulation 108 : 965 970.
41. Gallagher MM, Magliano G, Yap YG, Padula M, Morgia V, Postorino C et al. (2006). Distribution and prognostic significance of QT intervals in the lowest half centile in 12 012 apparently healthy persons. Am J Cardiol 98 : 933 935.
42. Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P et al. (2006). Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 27 : 2440 2447.
43. Gordon E, Lozinskaya IM, Lin Z, Semus SF, Blaney FE, Willette RN et al. (2008). 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go- related gene potassium channels. Mol Pharmacol 73 : 639 651.
44. Grunnet M, Schultz Hansen R, Olesen SP (2008). hERG1 channel activators: A new anti-arrythmic principle. Prog Biophys Mol Biol 98 : 347 362.
45. Gussak I, Brugada P, Brugada J, Wright RS, Kopecky SL, Chaitman BR et al. (2000). Idiopathic short QT interval: a new clinical syndrome? Cardiology 94 : 99 102.
46. Hansen RS, Olesen SP, Grunnet M (2007). Pharmacological activation of rapid delayed rectifier potassium current suppresses bradycardia-induced triggered activity in the isolated guinea pig heart. J Pharmacol Exp Ther 321 : 996 1002.
47. Holbrook M, Malik M, Shah RR, Valentin JP (2009). Drug induced Shortening of the QT/QTc Interval: an emerging safety issue in drug research and development? J Pharmacol Toxicol Methods 59 : 21 28.
48. Hong K, Piper DR, Diaz-Valdecantos A, Brugada J, Oliva A, Burashnikov E et al. (2005). De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res 68 : 433 440. (Pubitemid 41566563)
49. ICH (2005a). International Conference on Harmonization Note for Guidance on the Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (ICH S7B) (CHMP/ICH/423/02). EMEA : London, 25 May 2005. http://www.emea.eu.int/pdfs/ human/ich/042302en.pdf [Accessed on 22 March 2007 H, Sakaguchi T, Ashihara T, Ding WG, Nagaoka I, Oka Y et al. (2009). A novel KCNH2 mutation as a modifier for short QT interval. Int J Cardiol (in press).
50. Jehi L, Najm IM (2008). Sudden unexpected death in epilepsy: impact, mechanisms, and prevention. Cleve Clin J Med 75 (Suppl. 2 S66 S70.
51. Jervell A, Lange-Nielsen F (1957). Congenital deaf-mutism, functional heart disease with prolongation of Q-T interval and sudden death. Am Heart J 54 : 59 68.
52. Jeyaraj D, Abernethy DP, Natarajan RN, Dettmer MM, Dikshteyn M, Meredith DM et al. (2008). IKr channel blockade to unmask occult congenital long QT syndrome. Heart Rhythm 5 : 2 7.
53. Johnson JN, Hofman N, Haglund CM, Cascino GD, Wilde AA, Ackerman MJ (2009). Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy. Neurology 72 : 224 231.
54. + channel. Mol Pharmacol 67 : 827 836.
55. Karjalainen J, Viitasalo M, Mänttäri M, Manninen V (1994). Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 23 : 1547 1553.
56. Kosar F, Ates F, Sahin I, Karincaoglu M, Yildirim B (2007). QT interval analysis in patients with chronic liver disease: a prospective study. Angiology 58 : 218 224.
57. de La Coussaye JE, Eledjam JJ, Bruelle P, Peray PA, Bassoul BP, Gagnol JP et al. (1993). Electrophysiologic and arrhythmogenic effects of the potassium channel agonist BRL 38227 in anesthetized dogs. J Cardiovasc Pharmacol 22 : 722 730.
58. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H (2007). Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 4 : 603 607.
59. Levine SA, Woodworth CR (1958). Congenital deaf-mutism, prolonged Q-T interval, syncopal attacks and sudden death. N Engl J Med 259 : 412 417.
60. Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R et al. (2008). Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol 154 : 1427 1438.
61. Lykke JA, Tarnow L, Parving HH, Hilsted J (2008). A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scand J Clin Lab Invest 12 : 1 6.
62. + channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C. Biochem Biophys Res Commun 334 : 441 449.
63. Makarov LM, Chuprova SN, Kiseleva II. (2004). QT interval shortening in families with history of sudden death at young age. [Russian Kardiologiia 44 : 51 56.
64. Malik M (2002). The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol 25 : 209 216.
65. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B (2007). Electrocardiographic reference ranges derived from 79 743 ambulatory subjects. J Electrocardiol 40 : 228 234.
66. Maury P, Hollington L, Duparc A, Brugada R (2005). Short QT syndrome: should we push the frontier forward? Heart Rhythm 2 : 1135 1137.
67. MHRA (2008). Medicines and Healthcare products Regulatory Agency Drug Analysis Prints forLamotrigine and Nicorandil. http://www.mhra.gov.uk/ Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/ YellowCarddata/Druganalysisprints/index.htm [Accessed on 4 January 2009 JC, Petersen EN, Folke PE, Ovesen L (1980). Antiarrhythmic properties of a neuroleptic butyrophenone, melperone, in acute myocardial infarction. A double-blind trial. Acta Med Scand 208 : 61 64.
68. Moriya M, Seto S, Yano K, Akahoshi M (2007). Two cases of short QT interval. Pacing Clin Electrophysiol 30 : 1522 1526.
69. Moss AJ (1993). Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 72 : 23B 25B.
70. Moss AJ (1999). The QT interval and torsade de pointes. Drug Safety 21 (Suppl. 1 5 10.
71. Naschitz J, Fields M, Isseroff H, Sharif D, Sabo E, Rosner I (2006). Shortened QT interval: a distinctive feature of the dysautonomia of chronic fatigue syndrome. J Electrocardiol 39 : 389 394.
72. Oka H, Mochio S, Sato H, Katayama K (1997). Prolongation of QTc interval in patients with Parkinson's disease. Eur Neurol 37 : 186 189.
73. Oosterhoff P, Oros A, Vos MA (2007). Beat-to-beat variability of repolarization: a new parameter to determine arrhythmic risk of an individual or identify proarrhythmic drugs. Anadolu Kardiyol Derg 7 (Suppl. 1 73 78.
74. Pearson EC, Woosley RL (2005). QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 14 : 747 753.
75. de Ponti F, Poluzzi E, Montanaro N (2001). Organising evidence on QT prolongation and occurrence of torsade de pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 57 : 185 209.
76. de Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N (2002). Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Safety 25 : 263 286.
77. Priori SG, Napolitano C, Schwartz PJ (1999). Low penetrance in the long-QT syndrome: clinical impact. Circulation 99 : 529 533.
78. Priori SG, Bloise R, Crotti L (2001). The long QT syndrome. Europace 3 : 16 27.
79. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M et al. (2003). Risk stratification in the long-QT syndrome. N Engl J Med 348 : 1866 1874.
80. Priori SG, Pandit SV, Rivolta I, Berenfeld O, Ronchetti E, Dhamoon A et al. (2005). A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 96 : 800 807.
81. Reinig MG, Engel TR (2007). The shortage of short QT intervals. Chest 132 : 246 249.
82. Robert E, Delye B, Aya G, Péray P, Juan JM, Sassine A et al. (1997). Comparison of proarrhythmogenic effects of two potassium channel openers, levcromakalim (BRL 38227) and nicorandil (RP 46417): a high-resolution mapping study on rabbit heart. J Cardiovasc Pharmacol 29 : 109 118.
83. Robert E, Aya AG, de la Coussaye JE, Péray P, Juan JM, Brugada J et al. (1999). Dispersion-based reentry: mechanism of initiation of ventricular tachycardia in isolated rabbit hearts. Am J Physiol 276 (2 Pt 2 H413 H423.
84. Robertson GA, January CT (2006). HERG trafficking and pharmacological rescue of LQTS-2 mutant channels. Handb Exp Pharmacol 171 : 349 355.
85. Roden DM (2006). Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 259 : 59 69.
86. Romano C, Gemme G, Pongiglione R (1963). Aritmie cardiache rare dell'ete'pediatrica. Clinica Pediatrica 45 : 656 683.
87. Saarinen K, Swan H, Kainulainen K, Toivonen L, Viitasalo M, Kontula K (1998). Molecular genetics of the long QT syndrome: two novel mutations of the KVLQT1 gene and phenotypic expression of the mutant gene in a large kindred. Hum Mutat 11 : 158 165.
88. Saikawa T, Tsumabuki S, Nakagawa M, Takakura T, Tamura M, Maeda T et al. (1988). QT intervals as an index of high serum calcium in hypercalcemia. Clin Cardiol 11 : 75 78.
89. Sani MU, Okeahialam BN (2005). QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc 97 : 1657 1661.
90. Schwartz PJ (2006). The congenital long QT syndromes from genotype to phenotype: clinical implications. J Intern Med 259 : 39 47.
91. Seebohm G, Pusch M, Chen J, Sanguinetti MC (2003). Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels. Circ Res 93 : 941 947.
92. Shah RR (2002). The significance of QT interval during drug development. Br J Clin Pharmacol 54 : 188 202.
93. Shah RR (2004a). Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Safety 27 : 145 172.
94. Shah RR (2004b). Interpretation of clinical ECG data: understanding the risk from non-antiarrhythmic drugs. In : Morganroth J, Gussak I (eds). Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical Research and Drug Development. Humana Press Inc : Totowa, NJ, pp. 259 298.
95. Shah RR (2005). Drugs, QTc interval and Final ICH E14 Guideline: an important milestone with challenges ahead. Drug Saf 28 : 1009 1028.
96. Shah RR (2007). Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP. Guidance. Drug Safety 30 : 1093 1110.
97. Shah RR, Hondeghem LM (2005). Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2 : 758 772.
98. Shah RR, Morganroth J (2008). Evaluating the QT-liability of a drug during its development. Pharm Med 22 : 151 164.
99. + channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long QT syndrome. Circulation 102 : 706 712.
100. Smiseth OA, Platou ES, Refsum H, Mjøs OD (1981). Haemodynamic and metabolic effects of the antiarrhythmic drug melperone during acute left ventricular failure in dogs. Cardiovasc Res 15 : 724 730. (Pubitemid 12164797)
101. So EL (2008). What is known about the mechanisms underlying SUDEP? Epilepsia 49 (Suppl. 9 93 98.
102. Sugao M, Fujiki A, Sakabe M, Nishida K, Tsuneda T, Iwamoto J et al. (2006). New quantitative methods for evaluation of dynamic changes in QT interval on 24 h Holter ECG recordings: QT interval in idiopathic ventricular fibrillation and long QT syndrome. Heart 92 : 201 207.
103. Sun Z, Milos PM, Thompson JF, Lloyd DB, Mank-Seymour A, Richmond J et al. (2004). Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced torsades de pointes. J Mol Cell Cardiol 37 : 1031 1039.
104. Takahara A, Nakamura Y, Sugiyama A (2008). Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone. Eur J Pharmacol 596 : 127 131.
105. Teh HS, Tan HJ, Loo CY, Raymond AA (2007). Short QTc in epilepsy patients without cardiac symptoms. Med J Malaysia 62 : 104 108.
106. Thomsen MB, Volders PG, Beekman JD, Matz J, Vos MA (2006). Beat-to-Beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes. J Am Coll Cardiol 48 : 1268 1276.
107. Tosaki A, Szerdahelyi P, Engelman RM, Das DK (1993). Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? J Pharmacol Exp Ther 267 : 1355 1362.
108. Van der Heyden MA, Smits ME, Vos MA (2008). Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol 153 : 406 409.
109. Van der Linde HJ, van Deuren B, Teisman A, Towart R, Gallacher DJ (2008). The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correction. Br J Clin Pharmacol 154 : 1474 1481.
110. Veglio M, Chinaglia A, Cavallo Perin P (2000). The clinical utility of QT interval assessment in diabetes. Diabetes Nutr Metab 13 : 356 365.
111. Vincent GM (2000). Long QT syndrome. Cardiol Clin 18 : 309 325.
112. Vincent GM (2003). The long-QT syndrome - bedside to bench to bedside. N Engl J Med 348 : 1837 1838.
113. Vincent GM, Timothy KW, Leppert M, Keating M (1992). The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 327 : 846 852.
114. Viskin S, Zeltser D, Ish-Shalom M, Katz A, Glikson M, Justo D et al. (2004). Is idiopathic ventricular fibrillation a short QT syndrome? Comparison of QT intervals of patients with idiopathic ventricular fibrillation and healthy controls. Heart Rhythm 1 : 587 591.
115. Ward OC (1964). A new familial cardiac syndrome in children. J Irish Med Assoc 54 : 103 106.
116. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC et al. (2002). Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105 : 1943 1948.
117. Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E et al. (2008). Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol 48 : 415 421.
118. Zareba W, Cygankiewicz I (2008). Long QT syndrome and short QT syndrome. Prog Cardiovasc Dis 51 : 264 278.
119. Zhou J, Augelli-Szafran CE, Bradley JA, Chen X, Koci BJ, Volberg WA et al. (2005). Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 68 : 876 884.